Australia (AU)

Exploring the Use of ICT in Job Crafting (2022) Handke L, De Boeck G, Parker SK, Kauffeld S Conference contribution, Conference Contribution (Some) refugees welcome: When is differentiating between refugees unlawful discrimination? (2022) Costello C, Foster M Journal article Determinants of oxygen utilization in breast cancer: Similarities between heart failure with preserved ejection fraction (2022) Haykowsky MJ, Kirkham AA, Li T, Pituskin E, Thompson RB, Paterson DI, Foulkes SJ, et al. Journal article, Review article Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey (2022) Thakare D, Naveen R, Pauling J, Ahmed S, Wincup C, Del Papa N, Sambataro G, et al. Conference contribution Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey (2022) Ahmed S, Naveen R, Pauling J, Thakare D, Wincup C, Del Papa N, Sambataro G, et al. Conference contribution Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys (2022) Naveen R, Joshi M, Sen P, Agarwal V, Shinjo S, Kardes S, Lilleker JB, et al. Conference contribution COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis (2022) Naveen R, Parodis I, Joshi M, Sen P, Kim M, Agarwal V, Kardes S, et al. Conference contribution COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey (2022) Dey M, Naveen R, Nikiphorou E, Sen P, Lilleker JB, Agarwal V, Kardes S, et al. Conference contribution Anterior Knee Pain Is Associated with 2-year Compartment Specific Patellofemoral Cartilage Worsening: The MOST Study (2022) Lanois C, Collins N, Neogi T, Guermazi A, Roemer F, Lavalley M, Nevitt M, et al. Conference contribution HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution